ZeNix trial success announced

15 July 2021

The ZeNix trial tested the BPaL regimen against highly drug-resistant TB, with lower levels of Linezolid to reduce toxicity. This combination was still effective at curing TB and fewer side effects were reported.

CL3 laboratory worker with ZeNix logo

The results of ZeNix, a TB Alliance-sponsored Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.1 The results from the trial, which was led by TB Alliance, a non-profit TB drug developer, were announced ahead of an oral abstract presentation next week at the 11th IAS Conference on HIV Science.

The UCL Centre for Clinical Microbiology (CCM) was the central laboratory / laboratory monitoring lead and MRC Clinical Trials Unit at UCL was the statistical lead for this trial.

More information can be found here.

1. Conradie F. (2021) July 21. High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid [Conference presentation]. IAS 2021, Berlin, Germany.

The image shows Dr Julio Ortiz Canseco working in one of the CCM's containment level 3 laboratories (all rights reserved).